Possibility of TAS-102 as an Early Line Therapy Against Advanced Colorectal Cancer

Taichi Yoshida, Koji Fukuda, Daiki Taguchi, Kazuhiro Shimazu, Masahiro Inoue and Hiroyuki Shibata

Introduction: New drugs have improved the outcome of metastatic colorectal cancer treatment. In Japan, more than 10 agents with at least seven different mechani..మరిన్ని చూడండి»

Natalizumab to Fingolimod Switching in Multiple Sclerosis: Results from a “Real Word” Retrospective Analysis

Sarah Rasia, Cinzia Cordioli, Nicola De Rossi, Fabiana Pimazzoni, Cristina Scarpazza, Luisa Imberti and Ruggero Capra

Fingolimod is an alternative for patients with multiple sclerosis who discontinue natalizumab because of leukoencephalopathy risk. However, the interruption of natalizumab might..మరిన్ని చూడండి»

Evaluative study on the good use of the drug in Algeria

M.L Assad, K. Ait Hammou, N. Loumi

Pharmacovigilance is defined by the World Health Organization (WHO) as: "science and activities related to the detection, evaluation, understanding and prevention of advers..మరిన్ని చూడండి»

The Future of Preventative Medicine: Health Promotion Programs as a Tool to Reduce Administrative Costs and Improve Health Outcomes

Haley Matthews

Patient-centered care evolves around proper coordination between healthcare providers in consultation with patient needs. Oftentimes, children play a passive role in their healt..మరిన్ని చూడండి»

Registration of Increased Risk of Brain Cancer after the Diagnosis of Multiple Sclerosis

Bjørn A Nexø, Erzsébet Horváth-Puhó and Jens Sundbøll

Background: We studied the cancer comorbidity of 18,212 Danish Multiple Sclerosis (MS) patients.

Methods: Using data from the Danish Na..మరిన్ని చూడండి»

Healthcare without health insurance: a progress report on the peer to peer healthcare payment platform architecture

Ashoke Bose

A complete review of literature on healthcare policy and cost analysis is beyond the scope of this report. The lecture notes (HBS) are useful in understanding the fundamental di..మరిన్ని చూడండి»